Quick Facts
- • Primary components: EPA, DHA, ALA
- • For depression/ADHD: EPA-dominant formulas (EPA:DHA ≥2:1) are required
- • For prenatal cognition: DHA-dominant preferred
- • Therapeutic dose range: 1-3g combined EPA+DHA daily
- • Time to effect: 3-4 months for membrane incorporation
Omega-3 fatty acids are a family of polyunsaturated lipids with three principal forms: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA). EPA and DHA are found in fatty fish and algae and are biologically active; ALA (found in flaxseed, chia, walnuts) requires conversion to EPA and DHA, which occurs inefficiently in humans (approximately 5-10% for EPA, less than 1% for DHA).
The EPA-to-DHA ratio substantially determines clinical effect. For depression, anxiety, and ADHD-related indications, meta-analyses show efficacy only with EPA-dominant formulas where EPA represents at least 60% of total omega-3 content, at doses of 1-2g EPA daily. DHA-dominant or balanced formulas show null or paradoxically worse outcomes in these conditions (Sublette et al., 2011; Mocking et al., 2016). For prenatal/infant neurodevelopment and postpartum cognitive recovery, DHA-dominant formulas are preferred because DHA is the structural fatty acid of neural membranes.
Bioavailability varies by esterification: triglyceride and re-esterified triglyceride forms show 30-70% better absorption than ethyl ester forms, with phospholipid (krill oil) intermediate. For sensitive populations, enteric-coated capsules minimize fishy reflux. Quality matters: choose products tested for oxidation (TOTOX below 26) and third-party verified for heavy metals and PCBs. Effects require 3-4 months of consistent daily intake to reach steady-state membrane incorporation; shorter interventions consistently show null effects regardless of dose.
Adults with ADHD show consistent deficits in iron (ferritin <30 ng/mL in 84%), vitamin D (6.5 ng/mL lower), zinc, and magnesium. Supplementing these deficiencies produces measurable symptom improvements — particularly ferritin optimization (target >50 ng/mL), vitamin D (4000 IU/day), and zinc (15–30mg). L-tyrosine shows no benefit and develops tolerance. Screen for deficiencies before supplementing; prioritize iron and vitamin D testing.
28 sources 3/4 moderate Updated 2026-04-15
A seven-compound nutraceutical protocol (Omega-3 EPA ≥60%, Saffron 30mg, SAM-e, L-Methylfolate, Zinc, Curcumin+piperine, Magnesium glycinate) has demonstrated adjunctive efficacy for anxiety and depression across multiple RCTs and meta-analyses. Omega-3 EPA (≥1g/day) reduces depressive symptoms with effect size d≈0.61 in meta-analysis; Saffron 30mg/day matches fluoxetine 20mg in multiple head-to-head RCTs (n=40–60 per study). SAM-e (800–1600mg) and L-Methylfolate (15mg) show strong evidence specifically as SSRI augmentation. This protocol is intended as an adjunct to, not replacement for, standard psychiatric care.
22 sources 4/4 strong Updated 2026-04-15
Natural interventions for attention and focus show modest but real effects — especially for non-diagnosed 'brain fog' and subclinical attention difficulties. For clinically diagnosed ADHD, medication (stimulants or atomoxetine) remains the gold standard with the strongest evidence; natural compounds are best used as adjuncts or in cases where medication is declined. The strongest-evidenced natural interventions are: Magnesium (especially in those who are deficient), L-Theanine + low-dose caffeine (best acute focus combo), Omega-3 fatty acids EPA-dominant (particularly in children), and NAC for impulsivity. Effect sizes are consistently smaller than pharmaceutical interventions.
10 sources 3/4 moderate Updated 2026-04-15
The gut-brain axis is a real, bidirectional communication system — but the psychobiotic field suffers from a critical strain-specificity problem: evidence for one strain cannot be extrapolated to another, even within the same species. The strongest human RCT evidence comes from L. rhamnosus HN001 (perinatal mood, OR 0.44), B. longum NCC3001 (IBS-related depression with fMRI confirmation), and multi-strain combinations. Omega-3 and inositol provide complementary mechanisms. This protocol layers interventions by evidence strength across 3 phases, with dietary change as the non-negotiable foundation.
7 sources 3/4 moderate Updated 2026-04-15
For women unwilling or unable to use HRT, a targeted nutraceutical stack — anchored by magnesium bisglycinate, omega-3 fatty acids, and vitamin D3+K2 — offers moderate evidence for reducing vasomotor symptoms, improving sleep quality, and stabilizing mood during the menopausal transition. Maca (Lepidium meyenii) shows promising evidence for FSH/LH modulation and hot flash reduction, particularly in early postmenopausal women. DIM (diindolylmethane) may support favorable estrogen metabolism ratios but direct symptom evidence remains limited; it requires caution in women with estrogen-sensitive conditions. No supplement replaces HRT for severe vasomotor symptoms — be honest about that limit.
16 sources 3/4 moderate Updated 2026-04-15
Postpartum depletion is near-universal: >50% of women enter the postpartum period iron-deficient, with ferritin commonly <30 μg/L; optimal target is >50 μg/L for symptom resolution. Vitamin D deficiency affects 40–80% of new mothers and requires 2000–4000 IU/day for repletion. DHA depletion at delivery averages 48–50% vs. pre-pregnancy levels and directly correlates with mood and cognitive performance. A phased 6–12 month protocol combining iron + D3/K2 + magnesium glycinate + B12/methylfolate + omega-3 DHA/EPA resolves the majority of postpartum fatigue, brain fog, and telogen effluvium within 3–6 months.
18 sources 4/4 strong Updated 2026-04-15
Systematic supplementation targeting nutrient deficiencies can significantly reduce PPD risk. Key interventions: omega-3 (EPA-dominant, 2-3g/day), ferritin optimization (>50 μg/L), vitamin D (4000-6000 IU), magnesium glycinate (300-600mg), and L. rhamnosus HN001 probiotic. A three-phase protocol (prenatal → critical postpartum → extended) addresses the neurobiological cascade triggered by postpartum hormone collapse.
47 sources 4/4 strong Updated 2026-04-13